Kyverna Therapeutics (KYTX) Change in Accured Expenses (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Change in Accured Expenses data on file, last reported at -$6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 281.15% year-over-year to -$6.9 million; the trailing twelve-month figure through Mar 2026 stood at $35000.0 (down 97.96% YoY), and the FY2025 full-year result was $5.1 million, up 146.6% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$6.9 million, down from $3.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $3.0 million in Q4 2025 and bottomed at -$6.9 million in Q1 2026.
• The 4-year median for Change in Accured Expenses is $719000.0 (2023), against an average of $131000.0.
• The widest annual swing landed in 2025, when Change in Accured Expenses surged 583.97%; it then sank 281.15% in 2026.
• A 4-year view of Change in Accured Expenses shows it stood at $957000.0 in 2023, then tumbled by 53.71% to $443000.0 in 2024, then soared by 583.97% to $3.0 million in 2025, then slumped by 326.93% to -$6.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.9 million (Q1 2026), $3.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.

Peer Comparison